# Corneal Crosslinking Treatment Study

> **NCT04427956** · PHASE4 · COMPLETED · sponsor: **Region Skane** · enrollment: 54 (actual)

## Conditions studied

- Progressive Keratoconus

## Interventions

- **PROCEDURE:** Corneal crosslinking: CXL (UVA 9mW/cm2)
- **DRUG:** Isotonic riboflavin
- **DRUG:** Hypotonic riboflavin
- **PROCEDURE:** Iontophoresis

## Key facts

- **NCT ID:** NCT04427956
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2024-11-19
- **Final completion:** 2024-11-19
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04427956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04427956, "Corneal Crosslinking Treatment Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04427956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*